A novel peroxisome proliferator-activated receptor (PPAR)gamma agonist, NIP-222, reduces urinary albumin excretion in streptozotocin-diabetic mice independent of PPARgamma activation
NIP-222 is a novel peroxisome proliferator-activated receptor (PPAR)gamma agonist. This study provides evidence that NIP-222 decreases urinary albumin excretion (UAE) in diabetic mice independent of its PPARgamma activation. We compared the effect of NIP-222 and another PPARgamma agonist, troglitazo...
Gespeichert in:
| Veröffentlicht in: | Metabolism, clinical and experimental clinical and experimental, 2003-12, Vol.52 (12), p.1633-1637 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1637 |
|---|---|
| container_issue | 12 |
| container_start_page | 1633 |
| container_title | Metabolism, clinical and experimental |
| container_volume | 52 |
| creator | Yotsumoto, Takashi Naitoh, Takeshi Kanaki, Tatsuro Matsuda, Maho Tsuruzoe, Nobutomo |
| description | NIP-222 is a novel peroxisome proliferator-activated receptor (PPAR)gamma agonist. This study provides evidence that NIP-222 decreases urinary albumin excretion (UAE) in diabetic mice independent of its PPARgamma activation. We compared the effect of NIP-222 and another PPARgamma agonist, troglitazone, on UAE, plasma glucose level, blood pressure, and creatinine clearance (C(cr)) in streptozotocin (STZ)-induced diabetic mice. Treatment for 3 weeks with NIP-222 (30 mg/kg) was associated with a significant decrease in UAE without any change in blood pressure, creatinine clearance, or plasma glucose level. In contrast, UAE did not decrease in mice treated with troglitazone (300 mg/kg). These results indicate that NIP-222 has PPARgamma independent effects on UAE in diabetic mice and suggest that this agent may have potential to minimize the development and progression of diabetic nephropathy. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_71466284</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71466284</sourcerecordid><originalsourceid>FETCH-LOGICAL-g799-e22197efc2866d31ec7fb80b669145a8855c6fe0f214d3f882181382e1131dda3</originalsourceid><addsrcrecordid>eNo1UNtKAzEQ3QfF1uovSJ5EoQub7C37WIqXQtEifV-yyaRENsmaZEv1w_w-U1pfZpiZwzlzzkUyzTJSpVnRlJPk2vvPLMvqmlZXyQQXVdXgqpkmvwtk7B56NICzB-WtBjQ42ysJjgXrUsaD2rMAAjngMMQVethsFh-PO6Y1Q2xnjfJhjt5Wm5QQMo8wMXLwaHTKMPeNWN-NWhkEB-4gKGtQHHxwR64fGyxXJhWKdfHGkVYc4l3AALGYgKxER7Wz2OmXyHGTXErWe7g991myfX7aLl_T9fvLarlYp7u6aVIgBDc1SE5oVYkcA69lR7PuaL4oGaVlySsJmSS4ELmklGCKc0oA4xwLwfJZcn-ijZF8jeBDq5Xn0PfMgB19Wx-DJLSIwLszcOw0iHZwSkfz7X_Q-R9zsHxE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71466284</pqid></control><display><type>article</type><title>A novel peroxisome proliferator-activated receptor (PPAR)gamma agonist, NIP-222, reduces urinary albumin excretion in streptozotocin-diabetic mice independent of PPARgamma activation</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Yotsumoto, Takashi ; Naitoh, Takeshi ; Kanaki, Tatsuro ; Matsuda, Maho ; Tsuruzoe, Nobutomo</creator><creatorcontrib>Yotsumoto, Takashi ; Naitoh, Takeshi ; Kanaki, Tatsuro ; Matsuda, Maho ; Tsuruzoe, Nobutomo</creatorcontrib><description>NIP-222 is a novel peroxisome proliferator-activated receptor (PPAR)gamma agonist. This study provides evidence that NIP-222 decreases urinary albumin excretion (UAE) in diabetic mice independent of its PPARgamma activation. We compared the effect of NIP-222 and another PPARgamma agonist, troglitazone, on UAE, plasma glucose level, blood pressure, and creatinine clearance (C(cr)) in streptozotocin (STZ)-induced diabetic mice. Treatment for 3 weeks with NIP-222 (30 mg/kg) was associated with a significant decrease in UAE without any change in blood pressure, creatinine clearance, or plasma glucose level. In contrast, UAE did not decrease in mice treated with troglitazone (300 mg/kg). These results indicate that NIP-222 has PPARgamma independent effects on UAE in diabetic mice and suggest that this agent may have potential to minimize the development and progression of diabetic nephropathy.</description><identifier>ISSN: 0026-0495</identifier><identifier>PMID: 14669169</identifier><language>eng</language><publisher>United States</publisher><subject>Albuminuria - complications ; Albuminuria - drug therapy ; Angiotensin-Converting Enzyme Inhibitors - pharmacology ; Animals ; Blood Glucose - metabolism ; Blood Pressure - drug effects ; Body Weight - drug effects ; Captopril - pharmacology ; Chromans - pharmacology ; Diabetes Mellitus, Experimental - complications ; Diabetes Mellitus, Experimental - urine ; Diabetes Mellitus, Type 2 - genetics ; Diabetes Mellitus, Type 2 - metabolism ; Diabetic Nephropathies - metabolism ; Diabetic Nephropathies - pathology ; Genes, Reporter - genetics ; Hypoglycemic Agents - pharmacology ; Kidney - drug effects ; Kidney - pathology ; Luciferases - genetics ; Male ; Mice ; Organ Size - drug effects ; Plasmids - genetics ; Receptors, Cytoplasmic and Nuclear - agonists ; Receptors, Cytoplasmic and Nuclear - metabolism ; Thiazolidinediones - pharmacology ; Transcription Factors - agonists ; Transcription Factors - metabolism ; Troglitazone ; Urodynamics - drug effects</subject><ispartof>Metabolism, clinical and experimental, 2003-12, Vol.52 (12), p.1633-1637</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14669169$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yotsumoto, Takashi</creatorcontrib><creatorcontrib>Naitoh, Takeshi</creatorcontrib><creatorcontrib>Kanaki, Tatsuro</creatorcontrib><creatorcontrib>Matsuda, Maho</creatorcontrib><creatorcontrib>Tsuruzoe, Nobutomo</creatorcontrib><title>A novel peroxisome proliferator-activated receptor (PPAR)gamma agonist, NIP-222, reduces urinary albumin excretion in streptozotocin-diabetic mice independent of PPARgamma activation</title><title>Metabolism, clinical and experimental</title><addtitle>Metabolism</addtitle><description>NIP-222 is a novel peroxisome proliferator-activated receptor (PPAR)gamma agonist. This study provides evidence that NIP-222 decreases urinary albumin excretion (UAE) in diabetic mice independent of its PPARgamma activation. We compared the effect of NIP-222 and another PPARgamma agonist, troglitazone, on UAE, plasma glucose level, blood pressure, and creatinine clearance (C(cr)) in streptozotocin (STZ)-induced diabetic mice. Treatment for 3 weeks with NIP-222 (30 mg/kg) was associated with a significant decrease in UAE without any change in blood pressure, creatinine clearance, or plasma glucose level. In contrast, UAE did not decrease in mice treated with troglitazone (300 mg/kg). These results indicate that NIP-222 has PPARgamma independent effects on UAE in diabetic mice and suggest that this agent may have potential to minimize the development and progression of diabetic nephropathy.</description><subject>Albuminuria - complications</subject><subject>Albuminuria - drug therapy</subject><subject>Angiotensin-Converting Enzyme Inhibitors - pharmacology</subject><subject>Animals</subject><subject>Blood Glucose - metabolism</subject><subject>Blood Pressure - drug effects</subject><subject>Body Weight - drug effects</subject><subject>Captopril - pharmacology</subject><subject>Chromans - pharmacology</subject><subject>Diabetes Mellitus, Experimental - complications</subject><subject>Diabetes Mellitus, Experimental - urine</subject><subject>Diabetes Mellitus, Type 2 - genetics</subject><subject>Diabetes Mellitus, Type 2 - metabolism</subject><subject>Diabetic Nephropathies - metabolism</subject><subject>Diabetic Nephropathies - pathology</subject><subject>Genes, Reporter - genetics</subject><subject>Hypoglycemic Agents - pharmacology</subject><subject>Kidney - drug effects</subject><subject>Kidney - pathology</subject><subject>Luciferases - genetics</subject><subject>Male</subject><subject>Mice</subject><subject>Organ Size - drug effects</subject><subject>Plasmids - genetics</subject><subject>Receptors, Cytoplasmic and Nuclear - agonists</subject><subject>Receptors, Cytoplasmic and Nuclear - metabolism</subject><subject>Thiazolidinediones - pharmacology</subject><subject>Transcription Factors - agonists</subject><subject>Transcription Factors - metabolism</subject><subject>Troglitazone</subject><subject>Urodynamics - drug effects</subject><issn>0026-0495</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1UNtKAzEQ3QfF1uovSJ5EoQub7C37WIqXQtEifV-yyaRENsmaZEv1w_w-U1pfZpiZwzlzzkUyzTJSpVnRlJPk2vvPLMvqmlZXyQQXVdXgqpkmvwtk7B56NICzB-WtBjQ42ysJjgXrUsaD2rMAAjngMMQVethsFh-PO6Y1Q2xnjfJhjt5Wm5QQMo8wMXLwaHTKMPeNWN-NWhkEB-4gKGtQHHxwR64fGyxXJhWKdfHGkVYc4l3AALGYgKxER7Wz2OmXyHGTXErWe7g991myfX7aLl_T9fvLarlYp7u6aVIgBDc1SE5oVYkcA69lR7PuaL4oGaVlySsJmSS4ELmklGCKc0oA4xwLwfJZcn-ijZF8jeBDq5Xn0PfMgB19Wx-DJLSIwLszcOw0iHZwSkfz7X_Q-R9zsHxE</recordid><startdate>200312</startdate><enddate>200312</enddate><creator>Yotsumoto, Takashi</creator><creator>Naitoh, Takeshi</creator><creator>Kanaki, Tatsuro</creator><creator>Matsuda, Maho</creator><creator>Tsuruzoe, Nobutomo</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>200312</creationdate><title>A novel peroxisome proliferator-activated receptor (PPAR)gamma agonist, NIP-222, reduces urinary albumin excretion in streptozotocin-diabetic mice independent of PPARgamma activation</title><author>Yotsumoto, Takashi ; Naitoh, Takeshi ; Kanaki, Tatsuro ; Matsuda, Maho ; Tsuruzoe, Nobutomo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g799-e22197efc2866d31ec7fb80b669145a8855c6fe0f214d3f882181382e1131dda3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Albuminuria - complications</topic><topic>Albuminuria - drug therapy</topic><topic>Angiotensin-Converting Enzyme Inhibitors - pharmacology</topic><topic>Animals</topic><topic>Blood Glucose - metabolism</topic><topic>Blood Pressure - drug effects</topic><topic>Body Weight - drug effects</topic><topic>Captopril - pharmacology</topic><topic>Chromans - pharmacology</topic><topic>Diabetes Mellitus, Experimental - complications</topic><topic>Diabetes Mellitus, Experimental - urine</topic><topic>Diabetes Mellitus, Type 2 - genetics</topic><topic>Diabetes Mellitus, Type 2 - metabolism</topic><topic>Diabetic Nephropathies - metabolism</topic><topic>Diabetic Nephropathies - pathology</topic><topic>Genes, Reporter - genetics</topic><topic>Hypoglycemic Agents - pharmacology</topic><topic>Kidney - drug effects</topic><topic>Kidney - pathology</topic><topic>Luciferases - genetics</topic><topic>Male</topic><topic>Mice</topic><topic>Organ Size - drug effects</topic><topic>Plasmids - genetics</topic><topic>Receptors, Cytoplasmic and Nuclear - agonists</topic><topic>Receptors, Cytoplasmic and Nuclear - metabolism</topic><topic>Thiazolidinediones - pharmacology</topic><topic>Transcription Factors - agonists</topic><topic>Transcription Factors - metabolism</topic><topic>Troglitazone</topic><topic>Urodynamics - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yotsumoto, Takashi</creatorcontrib><creatorcontrib>Naitoh, Takeshi</creatorcontrib><creatorcontrib>Kanaki, Tatsuro</creatorcontrib><creatorcontrib>Matsuda, Maho</creatorcontrib><creatorcontrib>Tsuruzoe, Nobutomo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Metabolism, clinical and experimental</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yotsumoto, Takashi</au><au>Naitoh, Takeshi</au><au>Kanaki, Tatsuro</au><au>Matsuda, Maho</au><au>Tsuruzoe, Nobutomo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A novel peroxisome proliferator-activated receptor (PPAR)gamma agonist, NIP-222, reduces urinary albumin excretion in streptozotocin-diabetic mice independent of PPARgamma activation</atitle><jtitle>Metabolism, clinical and experimental</jtitle><addtitle>Metabolism</addtitle><date>2003-12</date><risdate>2003</risdate><volume>52</volume><issue>12</issue><spage>1633</spage><epage>1637</epage><pages>1633-1637</pages><issn>0026-0495</issn><abstract>NIP-222 is a novel peroxisome proliferator-activated receptor (PPAR)gamma agonist. This study provides evidence that NIP-222 decreases urinary albumin excretion (UAE) in diabetic mice independent of its PPARgamma activation. We compared the effect of NIP-222 and another PPARgamma agonist, troglitazone, on UAE, plasma glucose level, blood pressure, and creatinine clearance (C(cr)) in streptozotocin (STZ)-induced diabetic mice. Treatment for 3 weeks with NIP-222 (30 mg/kg) was associated with a significant decrease in UAE without any change in blood pressure, creatinine clearance, or plasma glucose level. In contrast, UAE did not decrease in mice treated with troglitazone (300 mg/kg). These results indicate that NIP-222 has PPARgamma independent effects on UAE in diabetic mice and suggest that this agent may have potential to minimize the development and progression of diabetic nephropathy.</abstract><cop>United States</cop><pmid>14669169</pmid><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0026-0495 |
| ispartof | Metabolism, clinical and experimental, 2003-12, Vol.52 (12), p.1633-1637 |
| issn | 0026-0495 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71466284 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Albuminuria - complications Albuminuria - drug therapy Angiotensin-Converting Enzyme Inhibitors - pharmacology Animals Blood Glucose - metabolism Blood Pressure - drug effects Body Weight - drug effects Captopril - pharmacology Chromans - pharmacology Diabetes Mellitus, Experimental - complications Diabetes Mellitus, Experimental - urine Diabetes Mellitus, Type 2 - genetics Diabetes Mellitus, Type 2 - metabolism Diabetic Nephropathies - metabolism Diabetic Nephropathies - pathology Genes, Reporter - genetics Hypoglycemic Agents - pharmacology Kidney - drug effects Kidney - pathology Luciferases - genetics Male Mice Organ Size - drug effects Plasmids - genetics Receptors, Cytoplasmic and Nuclear - agonists Receptors, Cytoplasmic and Nuclear - metabolism Thiazolidinediones - pharmacology Transcription Factors - agonists Transcription Factors - metabolism Troglitazone Urodynamics - drug effects |
| title | A novel peroxisome proliferator-activated receptor (PPAR)gamma agonist, NIP-222, reduces urinary albumin excretion in streptozotocin-diabetic mice independent of PPARgamma activation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T12%3A38%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20novel%20peroxisome%20proliferator-activated%20receptor%20(PPAR)gamma%20agonist,%20NIP-222,%20reduces%20urinary%20albumin%20excretion%20in%20streptozotocin-diabetic%20mice%20independent%20of%20PPARgamma%20activation&rft.jtitle=Metabolism,%20clinical%20and%20experimental&rft.au=Yotsumoto,%20Takashi&rft.date=2003-12&rft.volume=52&rft.issue=12&rft.spage=1633&rft.epage=1637&rft.pages=1633-1637&rft.issn=0026-0495&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E71466284%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71466284&rft_id=info:pmid/14669169&rfr_iscdi=true |